Get the Stockscreener App
0.5355
1.25%
-0.0091
Xilio Therapeutics Inc stock is traded at $0.5355, with a volume of 245.20K.
It is down -1.25% in the last 24 hours and up +3.44% over the past month.
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies and immune cell engagers.
See More
Previous Close:
$0.5446
Open:
$0.566
24h Volume:
245.20K
Relative Volume:
0.53
Market Cap:
$39.34M
Revenue:
-
Net Income/Loss:
$-81.22M
P/E Ratio:
-0.1809
EPS:
-2.96
Net Cash Flow:
$-74.41M
1W Performance:
+0.20%
1M Performance:
+3.44%
6M Performance:
-23.15%
1Y Performance:
-40.86%
1-Day Range:
$0.5221
$0.566
1-Week Range:
$0.5132
$0.5719
52-Week Range:
$0.503
$1.18
Xilio Therapeutics Inc Stock (XLO) Company Profile
Name
Xilio Therapeutics Inc
Sector
Industry
Phone
617-833-1027
Address
828 WINTER STREET, WALTHAM
Compare XLO vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XLO
Xilio Therapeutics Inc
|
0.5355 | 40.00M | 0 | -81.22M | -74.41M | -2.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.70 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
762.45 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
722.13 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.03 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
291.37 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Xilio Therapeutics Inc Stock (XLO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-06-25 | Initiated | Leerink Partners | Outperform |
| Dec-21-22 | Initiated | Chardan Capital Markets | Buy |
| Jan-10-22 | Initiated | H.C. Wainwright | Buy |
| Nov-16-21 | Initiated | Cowen | Outperform |
| Nov-16-21 | Initiated | Guggenheim | Buy |
| Nov-16-21 | Initiated | Morgan Stanley | Overweight |
| Nov-16-21 | Initiated | Raymond James | Outperform |
View All
Xilio Therapeutics Inc Stock (XLO) Latest News
XLO Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Press Release: Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - 富途牛牛
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Bitget
Xilio Therapeutics to Present at the Leerink Partners Global Healthcare Conference - The Manila Times
Xilio Therapeutics announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
XLO PE Ratio & Valuation, Is XLO Overvalued - Intellectia AI
Is Xilio Therapeutics Inc. benefiting from innovation trendsPortfolio Performance Report & Free Technical Confirmation Trade Alerts - mfd.ru
Xilio Therapeutics Shareholders Approve Flexible Reverse Stock Split - The Globe and Mail
Xilio Therapeutics (NASDAQ: XLO) gains stockholder OK for reverse stock split range - Stock Titan
Entry Recap: Why is Xilio Therapeutics Inc stock going down2025 Top Gainers & Capital Efficient Trading Techniques - baoquankhu1.vn
Will Xilio Therapeutics Inc. stock reach Wall Street targetsWeekly Investment Report & Fast Gaining Stock Strategy Reports - mfd.ru
Bain Capital Life Sciences reports 9.99% Xilio (XLO) stake capped by blocker - Stock Titan
What is the long term forecast for Xilio Therapeutics Inc. stockEarnings Overview Report & High Yield Equity Trading Tips - mfd.ru
Frazier Life Sciences funds detail Xilio Therapeutics (XLO) ownership and warrants - Stock Titan
What is the Moat Score of Xilio Therapeutics Inc.July 2025 Opening Moves & Daily Volume Surge Trade Alerts - mfd.ru
Xilio Therapeutics Prices Pre-Funded Warrant Offering Financing - TipRanks
Xilio Therapeutics Signs Underwriting Agreement With Leerink Partners - TradingView
Xilio Therapeutics (NASDAQ: XLO) raises ~$40M via 74.8M pre-funded warrants - Stock Titan
Gilead discloses 19.9% stake in Xilio Therapeutics (XLO) ownership filing - Stock Titan
Xilio Therapeutics Launches Pre-Funded Warrant Offering - Intellectia AI
Xilio Therapeutics Prices $40M Underwritten Offering - National Today
Xilio Therapeutics Prices Pre-Funded Warrant Offering - Intellectia AI
Xilio Therapeutics Announces Pricing of Underwritten Offering - Yahoo Finance
Xilio Therapeutics announces pricing of underwritten offering - marketscreener.com
Xilio Therapeutics Announces Pricing Of Underwritten Offering - TradingView
Xilio Therapeutics Announces Pricing of $40 Million Underwritten Offering of Pre-Funded Warrants - Quiver Quantitative
Cancer drug developer Xilio raises $40M in warrant deal - Stock Titan
Can Xilio Therapeutics Inc. expand into new marketsDollar Strength & Entry Point Confirmation Signals - mfd.ru
Xilio (XLO) cuts Leerink-led stock offering capacity to $9.5M - Stock Titan
Xilio Therapeutics (NASDAQ:XLO) Shares Up 0.9% – Still a Buy? - Defense World
Earnings Risk: Can Xilio Therapeutics Inc deliver alphaM&A Rumor & Verified Short-Term Trading Plans - baoquankhu1.vn
Aug PostEarnings: Can Xilio Therapeutics Inc deliver alphaWeekly Investment Recap & Weekly Stock Breakout Alerts - baoquankhu1.vn
Growth Recap: How cyclical is Xilio Therapeutics Incs revenue streamCPI Data & Risk Controlled Stock Pick Alerts - baoquankhu1.vn
Sell Signal: What is AAMUs market position2025 Dividend Review & High Win Rate Trade Tips - baoquankhu1.vn
Highs Report: What is Espey Mfg Electronics Corps market positionJuly 2025 Trends & Technical Pattern Recognition Alerts - baoquankhu1.vn
US Stocks Recap: Whats the fair value of Xilio Therapeutics Inc stockShort Setup & Technical Pattern Alert System - baoquankhu1.vn
Growth Recap: What is the long term forecast for Xilio Therapeutics Inc stock2025 Volatility Report & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
Xilio Therapeutics (NASDAQ: XLO) reverse split vote to keep listing - Stock Titan
Performance Recap: Is Xilio Therapeutics Inc in accumulation or distribution phase2025 Biggest Moves & High Win Rate Trade Alerts - baoquankhu1.vn
Update Recap: Can Xilio Therapeutics Inc sustain earnings growthJuly 2025 Final Week & Weekly Hot Stock Watchlists - baoquankhu1.vn
Xilio Therapeutics Highlights Upcoming Milestones and Recent Corporate Updates - Sahm
What dividend safety score for Xilio Therapeutics Inc. stockPortfolio Update Report & Technical Pattern Based Signals - Улправда
How Xilio Therapeutics Inc. stock reacts to bond yieldsWeekly Investment Summary & Weekly High Return Forecasts - Улправда
Is Xilio Therapeutics Inc. stock a contrarian buyEarnings Summary Report & Weekly Sector Rotation Insights - Улправда
Xilio Therapeutics secures $35.8 million from warrant exercises By Investing.com - Investing.com India
Xilio Therapeutics, Inc. Announces Change of Chair of the Board of Directors - MarketScreener
Why Xilio Therapeutics Inc. stock attracts high net worth investorsWeekly Trend Summary & Breakout Confirmation Alerts - ulpravda.ru
Xilio Therapeutics extends cash runway into 2027 - MSN
Xilio Therapeutics Inc appoints Sara Bonstein as chair of board - MarketScreener
Xilio Therapeutics Announces Leadership Transition and Pipeline Updates - TipRanks
Xilio Therapeutics Inc Stock (XLO) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.07%
0.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):